ANDA 88849, held by Chartwell Rx. Hydralazine Hydrochloride.
As of Nov 16, 2026, ANDA 88849 (Hydralazine Hydrochloride), held by Chartwell Rx, was first approved by FDA on Feb 26, 1985, with 7 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 26, 1985 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Hydralazine Hydrochloride100MG ยท tablet;oral | Hydralazine Hydrochloride | Discontinued |
| Oct 6, 2000 | Supplement 13Manufacturing | Approved | None posted |
| Sep 9, 1992 | Supplement 10Labeling | Approved | None posted |
| Feb 14, 1992 | Supplement 8Labeling | Approved | None posted |
| Jan 28, 1991 | Supplement 7Labeling | Approved | None posted |
| Jan 28, 1991 | Supplement 6Manufacturing | Approved | None posted |
| Mar 10, 1988 | Supplement 5Manufacturing | Approved | None posted |
| Jun 13, 1986 | Supplement 1Manufacturing | Approved | None posted |
| Feb 26, 1985 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters